Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 896432, 9 pages
http://dx.doi.org/10.1155/2015/896432
Review Article

hERG1 Potassium Channels: Novel Biomarkers in Human Solid Cancers

1Experimental and Clinical Medicine, University of Florence, Viale GB Morgagni 50, 50134 Florence, Italy
2General Surgery and Surgical Oncology, Careggi University Hospital, Largo A Brambilla 3, 50134 Florence, Italy
3Breast Unit Surgery, Department of Oncology, Careggi University Hospital, Largo A Brambilla 3, 50134 Florence, Italy

Received 24 October 2014; Revised 16 February 2015; Accepted 24 February 2015

Academic Editor: Ondrej Topolcan

Copyright © 2015 Elena Lastraioli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. D'Amico, L. Gasparoli, and A. Arcangeli, “Potassium channels: novel emerging biomarkers and targets for therapy in cancer,” Recent Patents on Anti-Cancer Drug Discovery, vol. 8, no. 1, pp. 53–65, 2013. View at Google Scholar · View at Scopus
  2. J. W. Warmke and B. Ganetzky, “A family of potassium channel genes related to eag in Drosophila and mammals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 8, pp. 3438–3442, 1994. View at Publisher · View at Google Scholar · View at Scopus
  3. J. I. Vandenberg, M. D. Perry, M. J. Perrin, S. A. Mann, Y. Ke, and A. P. Hill, “hERG K+ channels: structure, function, and clinical significance,” Physiological Reviews, vol. 92, no. 3, pp. 1393–1478, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Bianchi, B. Wible, A. Arcangeli et al., “herg encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells?” Cancer Research, vol. 58, no. 4, pp. 815–822, 1998. View at Google Scholar · View at Scopus
  5. A. Arcangeli, B. Rosati, A. Cherubini et al., “HERG- and IRK-like inward rectifier currents are sequentially expressed during neuronal development of neural crest cells and their derivatives,” European Journal of Neuroscience, vol. 9, no. 12, pp. 2596–2604, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Arcangeli, L. Bianchi, A. Becchetti et al., “A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells,” Journal of Physiology (London), vol. 489, no. 2, pp. 455–471, 1995. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Arcangeli, B. Rosati, A. Cherubini et al., “Long term exposure to Retinoic Acid induces the expression of IRK1 channels in HERG channel-endowed neuroblastoma cells,” Biochemical and Biophysical Research Communications, vol. 244, no. 3, pp. 706–711, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Arcangeli, B. Rosati, O. Crociani et al., “Modulation of HERG current and herg gene expression during retinoic acid treatment of human neuroblastoma cells: potentiating effects of BDNF,” Journal of Neurobiology, vol. 40, no. 2, pp. 214–225, 1999. View at Publisher · View at Google Scholar
  9. A. Cherubini, G. L. Taddei, O. Crociani et al., “HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium,” British Journal of Cancer, vol. 83, no. 12, pp. 1722–1729, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Lastraioli, L. Guasti, O. Crociani et al., “herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells,” Cancer Research, vol. 64, no. 2, pp. 606–611, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Lastraioli, A. Taddei, L. Messerini et al., “hERG1 channels in human esophagus: evidence for their aberrant expression in the malignant progression of Barrett's esophagus,” Journal of Cellular Physiology, vol. 209, no. 2, pp. 398–404, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Feng, Y. Junbo, X. Pan et al., “HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96,” Oncotarget, vol. 5, no. 14, pp. 5832–5844, 2014. View at Google Scholar
  13. V. Asher, R. Khan, A. Warren et al., “The Eag potassium channel as a new prognostic marker in ovarian cancer,” Diagnostic Pathology, vol. 5, article 78, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Masi, A. Becchetti, R. Restano-Cassulini et al., “hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines,” British Journal of Cancer, vol. 93, no. 7, pp. 781–792, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Pillozzi, M. F. Brizzi, M. Balzi et al., “HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors,” Leukemia, vol. 16, no. 9, pp. 1791–1798, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. G. A. M. Smith, H.-W. Tsui, E. W. Newell et al., “Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells,” Journal of Biological Chemistry, vol. 277, no. 21, pp. 18528–18534, 2002. View at Google Scholar · View at Scopus
  17. H. Wang, Y. Zhang, L. Cao et al., “HERG K+ channel, a regulator of tumor cell apoptosis and proliferation,” Cancer Research, vol. 62, no. 17, pp. 4843–4848, 2002. View at Google Scholar · View at Scopus
  18. O. Crociani, L. Guasti, M. Balzi et al., “Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells,” The Journal of Biological Chemistry, vol. 278, no. 5, pp. 2947–2955, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Arcangeli, S. Pillozzi, and A. Becchetti, “Targeting ion channels in leukemias: a new challenge for treatment,” Current Medicinal Chemistry, vol. 19, no. 5, pp. 683–696, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Ferlay, I. Soerjomataram, M. Ervik et al., GLOBOCAN 2012 v1.0: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, International Agency for Research on Cancer, Lyon, France, 2013, http://globocan.iarc.fr.
  21. American Cancer Society, Cancer Facts & Figures, American Cancer Society, 2014.
  22. National Cancer Institute, Fast Stats: An Interactive Tool for Access to SEER Cancer Statistics, Surveillance Research Program, National Cancer Institute, 2014, http://seer.cancer.gov/faststats/.
  23. D. Thomas, B. Gut, S. Karsai et al., “Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 368, no. 1, pp. 41–48, 2003. View at Google Scholar
  24. K. Lansu and S. Gentile, “Potassium channel activation inhibits proliferation of breast cancer cells by activating a senescence program,” Cell Death & Disease, vol. 4, no. 6, article e652, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. S. Cicek, D. C. Koestler, B. L. Fridley et al., “Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel,” Human Molecular Genetics, vol. 22, no. 15, Article ID ddt160, pp. 3038–3047, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. X.-W. Ding, H.-S. Luo, B. Lou, D.-Q. Xu, and S. Gao, “Overexpression of hERG1 in resected esophageal squamous cell carcinomas: a marker for poor prognosis,” Journal of Surgical Oncology, vol. 97, no. 1, pp. 57–62, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Lastraioli, F. G. Campani, A. Taddei et al., “hERG1 channels are overexpressed in human gastric cancer and their activity regulates cell proliferation: a novel prognostic and therapeutic target?” in Proceedings of 6th International Gastric Cancer Congress (IGCC '05), pp. 151–154, Yokohama, Japan, May 2005.
  28. R. Zhang, P. Tian, Q. Chi et al., “Human ether-à-go-go-related gene expression is essential for cisplatin to induce apoptosis in human gastric cancer,” Oncology Reports, vol. 27, no. 2, pp. 433–440, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. X.-D. Shao, K.-C. Wu, X.-Z. Guo, M.-J. Xie, J. Zhang, and D.-M. Fan, “Expression and significance of HERG protein in gastric cancer,” Cancer Biology & Therapy, vol. 7, no. 1, pp. 45–50, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. X. W. Ding, W. B. Yang, S. Gao et al., “Prognostic significance of hERG1 expression in gastric cancer,” Digestive Diseases and Sciences, vol. 55, no. 4, pp. 1004–1010, 2010. View at Publisher · View at Google Scholar
  31. O. Crociani, E. Lastraioli, L. Boni et al., “HERG1 channels regulate VEGF-A secretion in human gastric cancer: clinicopathological correlations and therapeutical implications,” Clinical Cancer Research, vol. 20, no. 6, pp. 1502–1512, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. S.-Z. Chen, M. Jiang, and Y.-S. Zhen, “HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin,” Cancer Chemotherapy and Pharmacology, vol. 56, no. 2, pp. 212–220, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. O. Crociani, F. Zanieri, S. Pillozzi et al., “Herg1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer,” Scientific Reports, vol. 3, article 3308, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Lastraioli, L. Bencini, E. Bianchini et al., “hERG1 channels and Glut-1 as independent prognostic indicators of worse outcome in stage I and II colorectal cancer: A Pilot Study,” Translational Oncology, vol. 5, no. 2, pp. 105–112, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Glassmeier, K. Hempel, I. Wulfsen, C. K. Bauer, U. Schumacher, and J. R. Schwarz, “Inhibition of HERG1 K+ channel protein expression decreases cell proliferation of human small cell lung cancer cells,” Pflügers Archiv, vol. 463, no. 2, pp. 365–376, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Bray, A. Jemal, N. Grey, J. Ferlay, and D. Forman, “Global cancer transitions according to the Human Development Index (2008–2030): a population-based study,” The Lancet Oncology, vol. 13, no. 8, pp. 790–801, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. D. R. Youlden, S. M. Cramb, N. A. M. Dunn, J. M. Muller, C. M. Pyke, and P. D. Baade, “The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality,” Cancer Epidemiology, vol. 36, no. 3, pp. 237–248, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. D. R. Youlden, S. M. Cramb, C. Har Yip, and P. D. Baade, “Incidence and mortality of female breast cancer in the Asia-Pacific region,” Cancer Biology & Medicine, vol. 11, pp. 101–115, 2014. View at Publisher · View at Google Scholar
  39. M. Malvezzi, P. Bertuccio, F. Levi, C. La Vecchia, and E. Negri, “European cancer mortality predictions for the year 2014,” Annals of Oncology, vol. 25, no. 8, pp. 1650–1656, 2014. View at Publisher · View at Google Scholar
  40. N. Wolmark and B. Fisher, “Surgery in the primary treatment of breast cancer,” Breast Cancer Research and Treatment, vol. 1, no. 4, pp. 339–348, 1981. View at Publisher · View at Google Scholar · View at Scopus
  41. J. S. Parker, M. Mullins, M. C. Cheang et al., “Supervised risk predictor of breast cancer based on intrinsic subtypes,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1160–1167, 2009. View at Publisher · View at Google Scholar
  42. A. Goldhirsch, E. P. Winer, A. S. Coates et al., “Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013,” Annals of Oncology, vol. 29, no. 4, pp. 2206–2223, 2013. View at Publisher · View at Google Scholar
  43. I. Kümler, M. K. Tuxen, and D. L. Nielsen, “A systematic review of dual targeting in HER2-positive breast cancer,” Cancer Treatment Reviews, vol. 40, no. 2, pp. 259–270, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. J.-H. Ko, E. A. Ko, W. Gu, I. Lim, H. Bang, and T. Zhou, “Expression profiling of ion channel genes predicts clinical outcome in breast cancer,” Molecular Cancer, vol. 12, no. 1, article 106, 2013. View at Publisher · View at Google Scholar
  45. W. H. Allum, J. M. Blazeby, S. M. Griffin, D. Cunningham, J. A. Jankowski, and R. Wong, “Guidelines for the management of oesophageal and gastric cancer,” Gut, vol. 60, no. 11, pp. 1449–1472, 2011. View at Publisher · View at Google Scholar
  46. A. Pennathur, M. K. Gibson, B. A. Jobe, and J. D. Luketich, “Oesophageal carcinoma,” The Lancet, vol. 381, no. 9864, pp. 400–412, 2013. View at Publisher · View at Google Scholar
  47. K. K. Wang and R. E. Sampliner, “Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus,” The American Journal of Gastroenterology, vol. 103, no. 3, pp. 788–797, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. S. G. Thrumurthy, M. A. Chaudry, D. Hochhauser, and M. Mughal, “The diagnosis and management of gastric cancer,” British Medical Journal, vol. 347, Article ID f6367, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. A. C. Ford, D. Forman, R. H. Hunt, Y. Yuan, and P. Moayyedi, “Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials,” British Medical Journal, vol. 348, Article ID A1614, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Penon, L. Cito, and A. Giordano, “Novel findings about management of gastric cancer: a summary from 10th IGCC,” World Journal of Gastroenterology, vol. 20, no. 21, pp. 8986–8992, 2014. View at Publisher · View at Google Scholar
  51. Y.-J. Bang, E. van Cutsem, A. Feyereislova et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Lastraioli, T. Lottini, L. Messerini, M. A. G. M. Butorano, C. Vindigni, and A. Tomezzoli, “hERG1 channel expression in gastric dysplasia,” in Proceedings of 10th International Green Computing Conference (IGCC '13), pp. 30–31, Verona, Italy, 2013.
  53. H. Brenner, C. Stock, and M. Hoffmeister, “Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality:systematic review and meta-analysis of randomised controlled trials and observational studies,” British Medical Journal, vol. 348, Article ID g2467, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Brenner, M. Kloor, and C. P. Pox, “Colorectal cancer,” The Lancet, vol. 383, no. 9927, pp. 1490–1502, 2014. View at Publisher · View at Google Scholar
  55. C. C. Pritchard and W. M. Grady, “Colorectal cancer molecular biology moves into clinical practice,” Gut, vol. 60, no. 1, pp. 116–129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. J. H. Dolderer, H. Schuldes, H. Bockhorn et al., “HERG1 gene expression as a specific tumor marker in colorectal tissues,” European Journal of Surgical Oncology, vol. 36, no. 1, pp. 72–77, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. J.-H. Gong, X.-J. Liu, B.-Y. Shang, S.-Z. Chen, and Y.-S. Zhen, “HERG K+ channel related chemosensitivity to sparfloxacin in colon cancer cells,” Oncology Reports, vol. 23, no. 6, pp. 1747–1756, 2010. View at Google Scholar · View at Scopus
  58. A. Fiore, L. Carraresi, A. Morabito et al., “Characterization of hERG1 channel role in mouse colorectal carcinogenesis,” Cancer Medicine, vol. 2, no. 5, pp. 583–594, 2013. View at Publisher · View at Google Scholar
  59. A. C. Tersmette, G. M. Petersen, G. J. A. Offerhaus et al., “Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer,” Clinical Cancer Research, vol. 7, no. 3, pp. 738–744, 2001. View at Google Scholar · View at Scopus
  60. D. Ansari, A. Rosendahl, J. Elebro, and R. Andersson, “Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer,” British Journal of Surgery, vol. 98, no. 8, pp. 1041–1055, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. E. Lastraioli, G. Perrone, A. Sette et al., “hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma,” British Journal of Cancer, 2015. View at Publisher · View at Google Scholar
  62. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. van Limbergen, and I. Vergote, “Endometrial cancer,” The Lancet, vol. 366, no. 9484, pp. 491–505, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. D. Thanapprapasr and K. Thanapprapasr, “Molecular therapy as a future strategy in endometrial cancer,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 6, pp. 3419–3423, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. H. M. J. Werner and H. B. Salvesen, “Current status of molecular biomarkers in endometrial cancer,” Current Oncology Reports, vol. 16, article 403, 2014. View at Publisher · View at Google Scholar
  65. S. Dutta, F.-Q. Wang, A. Phalen, and D. A. Fishman, “Biomarkers for ovarian cancer detection and therapy,” Cancer Biology and Therapy, vol. 9, no. 9, pp. 668–677, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. R. L. Baldwin, E. Nemeth, H. Tran et al., “BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study,” Cancer Research, vol. 60, no. 19, pp. 5329–5333, 2000. View at Google Scholar · View at Scopus
  67. E. Pujade-Lauraine, F. Hilpert, B. Weber et al., “Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial,” Journal of Clinical Oncology, vol. 32, no. 13, pp. 1302–1308, 2014. View at Publisher · View at Google Scholar
  68. A. Arcangeli and A. Becchetti, “New trends in cancer therapy: targeting ion channels and transporters,” Pharmaceuticals, vol. 3, no. 4, pp. 1202–1224, 2010. View at Publisher · View at Google Scholar · View at Scopus